The essential role of the pharmacist in adult vaccination

CPD
By
AP Staff
-

References 

  1. Morgan Poll. Roy Morgan image of professions survey. 2021. At: https://roymorgan-cms-dev.s3.ap-southeast-2.amazonaws.com/wp-content/uploads/2022/02/21014612/8691-Image-of-Professions-2021-April-2021.pdf  
  2. Australian Technical Advisory Group on Immunisation (ATAGI). Australian immunisation handbook. 2022. At: immunisationhandbook.health.gov.au  
  3. Breadon P, Burfurd I. A fair shot: how to close the vaccination gap. 2023. At: https://grattan.edu.au/wp-content/uploads/2023/11/A-fair-shot-How-to-close-the-vaccination-gap-Grattan-Institute-Report.pdf  
  4. Prodanovic D, Lapham K, Keenan R, et al. Enhancing adult vaccination coverage rates in Australia. 2021. At: www.immunisationcoalition.org.au/wp-content/uploads/2021/06/2021_06_28_Enhancing-adult-vaccination-coverage-rates-in-Aus_FINAL.pdf  
  5. Burson RC, Buttenheim AM, Armstrong A, et al. Community pharmacies as sites of adult vaccination: a systematic review. Hum Vaccin Immunother 2016;12(12):3146–59. 
  6. Healthengine. Australian Healthcare Index. 2023. At: https://australianhealthcareindex.com.au/australian-healthcare-index-june-2023-report/  
  7. Australian Institute of Health and Welfare (AIHW). 2009 Adult vaccination survey: summary results. Canberra, ACT: AIHW, 2011.  
  8. Menzies RI, Leask J, Royle J, et al. Vaccine myopia: adult vaccination also needs attention. Med J Aust 2017;206(6):238–39.  
  9. Raina MacIntyre C, Menzies R, Kpozehouen E, et al. Equity in disease prevention: vaccines for the older adults – a national workshop, Australia 2014. Vaccine 2016;34(46):5463–69. 
  10. Bach AT, Goad JA. The role of community pharmacy‐based vaccination in the USA: current practice and future directions. Integr Pharm Res Pract 2015;4:67. 
  11. Department of Health. National Immunisation Strategy for Australia 2019–2024. 2018. At: www.health.gov.au/sites/default/files/national-immunisation-strategy-for-australia-2019-2024_0.pdf  
  12. World Health Organization (WHO). Vaccines and immunization. 2024. At:  www.who.int/health-topics/vaccines-and-immunization#tab=tab_1  
  13. Doherty, TM, Del Guiudice G, Maggi S. Adult vaccination as part of a healthy lifestyle: moving from medical intervention to health promotion. Annals of Medicin 2019:5(2):128–40. 
  14. Esposito S, Principi N, Rezza G, et al. Vaccination of 50+ adults to promote healthy ageing in Europe: the way forward. Vaccine 2018;36(39):5819–24. 
  15. Australian Institute of Health and Welfare. The burden of vaccine preventable diseases in Australia – summary. 2019. At: www.aihw.gov.au/getmedia/ec9c16e9-970c-404e-9bfe-5e2541583f85/aihw-phe-242.pdf?inline=true  
  16. National Centre for Immunisation Research and Surveillance (NCIRS). Annual Immunisation Coverage Report 2021 Summary. 2022. At:  https://ncirs.org.au/annual-immunisation-coverage-report-2021-available-now   
  17. The Pharmaceutical Society of Australia. Pharmacist administered vaccinations. 2024. At: www.psa.org.au/state-vaccination-regulations/#1701652569667-898d6657-a4c6  
  18. Department of Health and Aged Care. Vaccination for healthy ageing. 2023. At: https://immunisationhandbook.health.gov.au/sites/default/files/2023-12/Infographic.%20Vaccination%20for%20healthy%20ageing.pdf  
  19. National Centre for Immunisation Research and Surveillance (NCIRS). Zoster (shingles) vaccines (Shingrix® [RZV] and Zostavax® [ZVL]) – frequently asked questions. 2022. At: https://ncirs.org.au/zoster-shingles/zoster-shingles-vaccines-shingrixr-rzv-and-zostavaxr-zvl-frequently-asked-questions  
  20. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019–32. 
  21. Lal H, Cunningham A, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087–96. 
  22. Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 2022;9(10):ofac485.   
  23. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus (RSV) immunizations. 2024. At: www.cdc.gov/vaccines/vpd/rsv/index.html   
  24. National Centre for Immunisation Research and Surveillance (NCIRS). Respiratory syncytial virus (RSV): Frequently asked questions (FAQs). 2022. At: https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/respiratory-syncytial-virus-rsv-frequently-asked   
  25. Recombinant respiratory syncytial virus (RSV) vaccines for older adults, and pregnant women to prevent disease in their infant. Aust Prescr 2024;47:100–1.  
  26. McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clinical Therapeutics 2017;39(8):1550–62. 
  27. Attwell K, Dube E, Gagneur A, et al. Vaccine acceptance: science, policy, and practice in a ‘post-fact’ world. Vaccine 2019;29;37(5):677–82.   
  28. Pharmaceutical Society of Australia. Practice Guidelines for the provision of immunisation services. 2020. At: https://my.psa.org.au/s/article/immunisation-guidelines   
  29. Therapeutic Goods Administration. Arexvy® Product Information. 2024. At: www.tga.gov.au/resources/auspmd/arexvy  
  30. Therapeutic Goods Administration. Abrysvo® Product Information. 2024. At: www.tga.gov.au/resources/auspmd/abrysvo-rsv-vaccine  
  31. GSK. Shingrix® Product Information. 2022. At: https://au.gsk.com/media/6786/shingrix_pi_au.pdf  
  32. Le LM, Veettil SK, Donaldson D, et al. The impact of pharmacist involvement on immunization uptake and other outcomes: An updated systematic review and meta-analysis. J Am Pharm Assoc 2022;62(5):1499–1513.e16. 
  33. Australian Government Department of Health and Aged Care Therapeutic Goods Administration. At: https://apps.tga.gov.au/Prod/msi/Search/Tradename/130229